IRIS - Res&Arch Institutional Research Information System - Research & Archive

Roila, Fausto
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.857
AS - Asia 2.532
EU - Europa 1.902
SA - Sud America 604
AF - Africa 82
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 2
AN - Antartide 1
Totale 7.983
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.760
SG - Singapore 1.353
IE - Irlanda 468
BR - Brasile 467
HK - Hong Kong 357
RU - Federazione Russa 354
IT - Italia 339
CN - Cina 283
FR - Francia 238
VN - Vietnam 159
DE - Germania 117
UA - Ucraina 76
IN - India 70
SE - Svezia 64
GB - Regno Unito 57
FI - Finlandia 52
AR - Argentina 47
BD - Bangladesh 46
CA - Canada 41
KR - Corea 37
TR - Turchia 33
IQ - Iraq 32
MX - Messico 32
PK - Pakistan 26
AT - Austria 25
ZA - Sudafrica 23
CO - Colombia 21
ES - Italia 21
NL - Olanda 21
ID - Indonesia 20
EC - Ecuador 19
JP - Giappone 19
PL - Polonia 19
SA - Arabia Saudita 18
BE - Belgio 17
PH - Filippine 15
UZ - Uzbekistan 14
VE - Venezuela 13
MA - Marocco 12
PY - Paraguay 11
CL - Cile 10
KE - Kenya 10
EG - Egitto 8
AE - Emirati Arabi Uniti 7
BO - Bolivia 7
DZ - Algeria 7
JM - Giamaica 7
JO - Giordania 7
MY - Malesia 7
DO - Repubblica Dominicana 6
TN - Tunisia 5
CH - Svizzera 4
KZ - Kazakistan 4
LT - Lituania 4
PE - Perù 4
TT - Trinidad e Tobago 4
AL - Albania 3
AZ - Azerbaigian 3
BG - Bulgaria 3
DK - Danimarca 3
ET - Etiopia 3
HN - Honduras 3
LB - Libano 3
NP - Nepal 3
PS - Palestinian Territory 3
TH - Thailandia 3
UY - Uruguay 3
BA - Bosnia-Erzegovina 2
BH - Bahrain 2
BY - Bielorussia 2
CR - Costa Rica 2
GE - Georgia 2
GH - Ghana 2
GR - Grecia 2
PT - Portogallo 2
RO - Romania 2
SN - Senegal 2
SR - Suriname 2
XK - ???statistics.table.value.countryCode.XK??? 2
AD - Andorra 1
AQ - Antartide 1
BB - Barbados 1
BF - Burkina Faso 1
BJ - Benin 1
CG - Congo 1
CZ - Repubblica Ceca 1
DJ - Gibuti 1
EU - Europa 1
HU - Ungheria 1
IS - Islanda 1
KW - Kuwait 1
LV - Lettonia 1
LY - Libia 1
MN - Mongolia 1
MR - Mauritania 1
NG - Nigeria 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
OM - Oman 1
PA - Panama 1
Totale 7.975
Salva come PNG Salva come JPEG
Città #
Singapore 937
Dublin 468
Hong Kong 356
Chandler 347
San Jose 322
Ashburn 224
Moscow 163
Boardman 162
Santa Clara 157
Altamura 135
Princeton 130
Medford 127
Lawrence 124
Lauterbourg 116
The Dalles 99
Los Angeles 81
Ho Chi Minh City 61
Perugia 57
São Paulo 54
New York 52
Beijing 46
Seoul 37
Jacksonville 35
San Mateo 33
Munich 29
Helsinki 26
Redmond 26
Andover 25
Ann Arbor 25
Hanoi 25
Nuremberg 23
Dallas 20
San Paolo di Civitate 20
Frankfurt am Main 19
Council Bluffs 18
Shanghai 18
Warsaw 18
Rome 17
Brussels 16
Montreal 16
Piscataway 16
Rio de Janeiro 16
Tokyo 16
Wilmington 16
Bologna 15
Chicago 15
Lahore 15
Brooklyn 14
Chennai 14
Houston 14
Baghdad 12
Guayaquil 12
Johannesburg 12
Orem 12
Brasília 11
Columbus 11
Napoli 11
San Francisco 11
Stockholm 11
Amsterdam 10
Denver 10
Falkenstein 10
Istanbul 10
Tashkent 10
Toronto 10
Turku 10
Atlanta 9
Boston 9
Dhaka 9
London 9
Mexico City 9
Mumbai 9
Ankara 8
Boydton 8
New Delhi 8
Belo Horizonte 7
Caracas 7
Des Moines 7
Guangzhou 7
Haiphong 7
Huskvarna 7
Jeddah 7
Medellín 7
Norwalk 7
Riyadh 7
Vienna 7
Amman 6
Manchester 6
Milan 6
Nairobi 6
Poplar 6
Porto Alegre 6
Surabaya 6
Tianjin 6
Woodbridge 6
Buenos Aires 5
Charlotte 5
Curitiba 5
Lappeenranta 5
Phoenix 5
Totale 5.222
Salva come PNG Salva come JPEG
Nome #
Primitive thyroid lymphomas 128
Supportive care in cancer—a MASCC perspective 126
Indoleamine 2,3-Dioxygenase 2 Immunohistochemical Expression in Resected Human Non-small Cell Lung Cancer: A Potential New Prognostic Tool 115
Efficacy of Pembrolizumab Monotherapy in Patients with or without Brain Metastases from Advanced Non-Small Cell Lung Cancer with a PD-L1 Expression ≥50% 113
Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy 109
Invasive ductal carcinoma arising in ectopic breast tissue of the axilla. Case report and review of the literature 107
Linee guida per la gestione dei pazienti affetti da melanoma cutaneo 105
Higher tlr7 gene expression predicts poor clinical outcome in advanced nsclc patients treated with immunotherapy 103
High incidence of brain metastases in HER2-overexpressing metastatic breast cancer (MBC) patients (PTS) responsive to weekly paclitaxel (P) and trastuzumab (T) treatment. 5 National Congress of Medical Oncology, Rome, 21-24 October 2003. 102
Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 >= 50% who progress on first-line immunotherapy: real-world data from a European cohort 96
High PD-L1/IDO-2 and PD-L2/IDO-1 Co-Expression Levels Are Associated with Worse Overall Survival in Resected Non-Small Cell Lung Cancer Patients 96
Surgical treatment of primitive thyroid lymphoma 90
Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab 89
2016 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following moderately emetogenic chemotherapy 89
Renal malignant solitary fibrous tumor with single lymph node involvement: report of unusual metastasis and review of the literature. 88
Cancer-related fatigue: ESMO Clinical Practice Guidelines for diagnosis and treatment 88
Aprepitant Versus Dexamethasone for Preventing Chemotherapy-Induced Delayed Emesis in Patients With Breast Cancer: A Randomized Double-Blind Study 85
Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal SubtypEs (CHANCE trial) 85
Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines 84
Sensitivity to immune checkpoint blockade in advanced non-small cell lung cancer patients with EGFR exon 20 insertion mutations 81
NICSO: Network Italiano Cure di Supporto in Oncologia – Italian Network for Supportive Care in Oncology 80
2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy 80
Raccomandazioni cliniche per il melanoma cutaneo 79
Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: A randomized, double-blind study 79
2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients 78
Use of Electronic Administrative Databases to Measure Quality Indicators of Breast Cancer Care: Experience of Five Regional Oncology Networks in Italy 78
Incidence, characteristics and treatment of fatigue in oncological cancer patients (PTS) in Italy: A cross-sectional study. 77
2016 updated MASCC/ESMO consensus recommendations: prevention of radiotherapy-induced nausea and vomiting 77
Acute emesis: moderately emetogenic chemotherapy 77
Optimizing the risk stratification of astrocytic tumors by applying the cIMPACT-NOW Update 3 signature: real-word single center experience 76
XPG mRNA expression levels modulate prognosis in resected non-small-cell lung cancer in conjunction with BRCA1 and ERCC1 expression. 75
Prevalence and spectrum of brca germline variants in central Italian high risk or familial breast/ovarian cancer patients: A monocentric study 75
Aprepitant versus metoclopramide, both combined with dexamethasone, for preventing cisplatin-induced delayed emesis: A randomized, double-blind study 75
Lorlatinib beyond progression plus platinum/pemetrexed for ALK-positive non-small cell lung cancer patients: report of two cases 74
Detection of egfr mutations in plasma cell-free tumor dna of tki-treated advanced-nsclc patients by three methodologies: Scorpion-arms, pnaclamp, and digital pcr 74
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial 74
Italian nivolumab expanded access programme: real-world results in non-squamous non-small cell lung cancer patients 73
Upfront pembrolizumab as an effective treatment start in patients with PD-L1 ≥ 50% non-oncogene addicted non-small cell lung cancer and asymptomatic brain metastases: an exploratory analysis 73
Repotrectinib’s Clinical Benefit and Its Brain Penetration in a Patient with Meningeal Carcinomatosis from G2032R-Mutated ROS-1 Positive Non-Small Cell Lung Cancer 72
Brigatinib for anaplastic lymphoma kinase-tyrosine kinase inhibitor naïve anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: An effective but still broken option 72
A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin 71
Ginger in the management of chemotherapy induced nausea and vomiting (CINV), in patients receiving high dose cisplatin: a multicenter, randomized, double-blind, placebo-controlled study 69
A new payment-by-results method for determining the fair price of new oncological drugs 68
Vascular events with immune checkpoint inhibitors in melanoma or non-small cell lung cancer: A systematic review and meta-analysis 68
BRAFV600 variant allele frequency predicts outcome in metastatic melanoma patients treated with BRAF and MEK inhibitors 67
Antiemetics in children receiving chemotherapy. MASCC/ESMO guideline update 2009 67
Impact of Circulating and Tissue Biomarkers in Adjuvant and Neoadjuvant Therapy for High-Risk Melanoma: Ready for Prime Time? 66
Correction: Repotrectinib’s Clinical Benefit and Its Brain Penetration in a Patient with Meningeal Carcinomatosis from G2032R-Mutated ROS-1 Positive Non-Small Cell Lung Cancer (Oncology and Therapy, (2024), 12, 1, (163-171), 10.1007/s40487-023-00251-6) 65
Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference 65
Aprepitant (AP) versus dexamethasone (D) for preventing delayed emesis induced by anthracyclines plus cyclophosphamide (A plus C) chemotherapy (CT) in breast cancer patients (pts): A double-blind, multicenter, randomized study 64
The impact of chemotherapy-induced nausea and vomiting on health-related quality of life 63
Optimal Management of Fatigue 63
RET Rearrangement as a Predictor of Unresponsiveness to Immunotherapy in Non-Small Cell Lung Cancer: Report of Two Cases with Review of the Literature 62
Real-World Results in Non-Squamous Non-Small Cell Lung Cancer Patients: Italian Nivolumab Expanded Access Program 62
DOACs in patients with brain cancers: promising but still a long way to go 61
Targeted therapy for advanced cutaneous melanoma 61
Inflamed Tumor Phenotype as Predictor of Long-Term Response to Pembrolizumab in an EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Patient with Acquired Resistance to Afatinib: a Case Report and Review of the Literature 61
Juvenile papillomatosis of the breast in young male: a case report 60
Chemotherapy-induced nausea and vomiting: ESMO Clinical Recommendations for prophylaxis 60
A review of olanzapine as an antiemetic in chemotherapy-induced nausea and vomiting and in palliative care patients 60
Incidence, characteristics and treatment of fatigue in oncological cancer patients (pts) in italy: a cross-section study 59
Prevention and treatment of pandemic influenza in cancer patients. 58
Aprepitant Versus Dexamethasone for Delayed Emesis: What Is the Role of the 5-Hydroxytryptamine Type 3 Receptor Antagonist Palonosetron? Reply 58
Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference 58
New antiemetic drugs 57
State of the art of antiemetic therapy 57
Immune checkpoint inhibitors for unresectable malignant pleural mesothelioma 57
Efficacy of neurokinin-1 receptor antagonists in the prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in patients receiving carboplatin-based chemotherapy: a systematic review and meta-analysis 56
Is There a Role for Multiple Lines of Anti-HER2 Therapies Administered Beyond Progression in HER2-Mutated Non-Small Cell Lung Cancer? A Case Report and Literature Review 55
Diagnosis and therapeutic management of parathyroid cancer, starting from the description of a clinical case 55
Hepatitis B in immunosuppressed cancer patients:pathogenesis, incidence and prophylaxis 54
Anticipatory Nausea, Risk Factors, and Its Impact on Chemotherapy-Induced Nausea and Vomiting: Results From the Pan European Emesis Registry Study 54
Efficacy and safety data from patients with advanced non-squamous NSCLC and brain metastases from the nivolumab expanded access programme (EAP) in Italy 54
Chemotherapy-induced nausea and vomiting: ESMO Clinical Recommendations for prophylaxis 54
Phase III Trial of Casopitant, a Novel Neurokinin-1 Receptor Antagonist, for the Prevention of Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy 53
Developing clinical recommendations for breast, colorectal, and lung cancer adjuvant treatments using the GRADE system: A study from the programma Ricerca e Innovazione Emilia Romagna oncology research group 52
Immunotherapy in Underrepresented Populations of Patients with Cancer: Do We Have Enough Evidence at Present? A Focus on Patients with Major Viral Infections and Autoimmune Disorders 51
Single-Dose Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Cisplatin Therapy: Randomized, Double-Blind Study Protocol-EASE 50
The cost of chemotherapy-induced nausea and vomiting in Italy 48
ICH in primary or metastatic brain cancer patients with or without anticoagulant treatment: a systematic review and meta-analysis 47
Management of chemotherapy extravasation: ESMO-EONS clinical practice guidelines 47
Evaluation of Risk Factors Predicting Chemotherapy-Related Nausea and Vomiting: Results From a European Prospective Observational Study 47
Prevalence, characteristics, and treatment of fatigue in oncological cancer patients in Italy: a cross-sectional study of the Italian Network for Supportive Care in Cancer (NICSO) 47
Conflict of interest among Italian medical oncologists: A national survey 47
Venous thromboembolism in cancer patients: ESMO Clinical Practice Guidelines for the management 46
Chemotherapy-induced nausea and vomiting 46
Molecular Profiling and Novel Therapeutic Strategies for Mucosal Melanoma: A Comprehensive Review 46
Palonosetron (PALO) plus dexamethasone (DEX) administered on day only prevents emesis and avoids prolonged DEX use in breast cancer patients treated with anthracycline/cyclophosphamide regimens 46
Proton Pump Inhibitors in cancer patients: How useful they are? A review of the most common indications for their use 45
Randomized trial of low-dose morphine versus weak opioids in moderate cancer pain 45
Cognitive impairment and chemotherapy: a brief overview 44
Management of venous thromboembolism in cancer patients: ESMO Clinical Recommendations 44
Update on anticancer drugs 44
PAINTER: Evaluation of eribulin tolerability and correlation between a set of polymorphisms and neuropathy in patients with metastatic breast cancer 44
Management of febrile neutropenia: ESMO Clinical Recommendations 44
Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines 44
Management of oral and gastrointestinal mucositis: ESMO Clinical Recommendations 43
Randomized, double-blind, dose-ranging trial of the oral neurokinin-1 receptor antagonist casopitant mesylate for the prevention of cisplatin-induced nausea and vomiting (Reprinted) 43
Targeting inflamed and non-inflamed melanomas: biological background and clinical challenges 42
Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy 42
Totale 6.763
Salva come PNG Salva come JPEG
Categoria #
all - tutte 43.896
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 43.896
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202130 0 0 0 0 0 0 0 0 0 10 16 4
2021/2022522 3 29 6 11 7 2 4 160 8 24 21 247
2022/20231.478 150 371 32 57 105 78 0 53 557 9 45 21
2023/2024585 28 47 25 14 10 2 128 13 39 40 107 132
2024/20251.771 9 165 27 63 198 74 50 147 470 116 268 184
2025/20263.543 306 230 263 462 495 242 615 237 402 291 0 0
Totale 8.151